血液科

订阅

MedSci主页 / 所有栏目 / 血液科

Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子

2022-05-28 网络 网络

慢性淋巴细胞白血病
关注

血清可溶性 CD23 (sCD23) 水平已被公认为慢性淋巴细胞白血病 (CLL) 患者的预后因素，该研究揭示了 CD23 定向治疗的活性和抗性机制。

血清可溶性 CD23 (sCD23) 水平已被公认为慢性淋巴细胞白血病(CLL) 患者的预后因素，但近期尚未分析其潜在相关性。一项回顾性研究对来自单一机构的 338 名 CLL、小淋巴细胞淋巴瘤或 CLL 型单克隆 B 细胞淋巴细胞增多症患者进行比较，诊断时有可用的 sCD23 水平。

比较 sCD23 ≤/>1000 UI/L 患者的基线特征和结局。sCD23 >1000 UI/L 的 140 名患者 (41%) 表现出不良风险的临床和生物学特征。高 sCD23 水平预示着首次治疗的时间更短（需要治疗的 5 年概率 60 对 20%，P<0.0001；风险比（HR）=1.72，P=0.003 在多变量模型中还包括 CLL 国际预后指数和绝对淋巴细胞计数），以及较差的 5 年总生存率（70% vs. 82%，P=0.0009）。

表1：在单变量和多变量分析中，首次治疗时间的预测因子

表2：治疗，反应和结果，全球和根据sCD23

图1：根据sCD23水平进行首次治疗的时间。

图2：根据sCD23水平的总体生存率。

总之，这些研究代表了迄今为止对CLL中sCD23水平的最大系列研究。研究发现，在新诊断的CLL患者中，sCD23>1000 UI/mL水平与不良的临床和生物学预后特征以及较差的OS相关。sCD23hi患者独立于CLL-IPI和淋巴细胞计数的TTFT较短。sCD23可以改善单个CLL患者的预后分层，预测无治疗生存期，并解释对选定的靶向治疗的反应机制。

 

原始出处：

Piñeyroa JA, Magnano L, Rivero A, Rivas-Delgado A, Nadeu F, Correa JG, Giné E, Villamor N, Filella X, Colomer D, López M, López-Oreja I, Costa D, Aymerich M, Beà S, López-Guillermo A, Campo E, Delgado J, Mozas P. Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematol Oncol. 2022 May 25. doi: 10.1002/hon.3027. Epub ahead of print. PMID: 35611996.

 

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 22 08:14:05 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992683, encodeId=982819926835a, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri May 12 15:14:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866619, encodeId=f0f61866619e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 14:14:05 CST 2023, time=2023-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302437, encodeId=3b32130243ea6, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310792, encodeId=12081310e9201, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2023-02-22 heli0118

    #淋巴细胞白血病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 22 08:14:05 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992683, encodeId=982819926835a, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri May 12 15:14:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866619, encodeId=f0f61866619e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 14:14:05 CST 2023, time=2023-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302437, encodeId=3b32130243ea6, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310792, encodeId=12081310e9201, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2023-05-12 ms306040998833292

    #治疗时间#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 22 08:14:05 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992683, encodeId=982819926835a, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri May 12 15:14:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866619, encodeId=f0f61866619e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 14:14:05 CST 2023, time=2023-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302437, encodeId=3b32130243ea6, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310792, encodeId=12081310e9201, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2023-02-15 docwu2019

    #Oncol#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 22 08:14:05 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992683, encodeId=982819926835a, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri May 12 15:14:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866619, encodeId=f0f61866619e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 14:14:05 CST 2023, time=2023-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302437, encodeId=3b32130243ea6, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310792, encodeId=12081310e9201, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-05-28 wetgdt

    #淋巴细胞#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 22 08:14:05 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992683, encodeId=982819926835a, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri May 12 15:14:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866619, encodeId=f0f61866619e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 14:14:05 CST 2023, time=2023-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302437, encodeId=3b32130243ea6, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310792, encodeId=12081310e9201, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-05-28 宋威

    #预测因子#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 22 08:14:05 CST 2023, time=2023-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992683, encodeId=982819926835a, content=<a href='/topic/show?id=f68c6465315' target=_blank style='color:#2F92EE;'>#治疗时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64653, encryptionId=f68c6465315, topicName=治疗时间)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri May 12 15:14:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866619, encodeId=f0f61866619e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 14:14:05 CST 2023, time=2023-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302437, encodeId=3b32130243ea6, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310792, encodeId=12081310e9201, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317726, encodeId=2f57131e72656, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat May 28 13:14:05 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-05-28 fengyi812

    #EMA#

    0

相关资讯

HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化

伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化

治疗慢性淋巴细胞白血病，双特异性γδ T细胞结合抗体LAVA-051获得FDA孤儿药认证

临床阶段生物技术公司LAVA Therapeutics NV今天宣布，美国食品和药品监督管理局（FDA）已授予该公司靶向CD1d的LAVA-05的孤儿药认证（ODD）。

HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。

阿卡拉布替尼治疗CLL患者的心血管不良事件发生率和因心血管事件而中断治疗的发生率相对较低。

Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系

全基因组关联研究（GWASs）已经发现了数千个与许多性状和疾病相关的遗传变异。看似不同的疾病可能有共同的易感性单核苷酸多态性（SNPs），因此可能有共同的生物机制或途径。对共同遗传关联的分析有助于解释

FDA叫停Ukoniq治疗慢性淋巴细胞白血病的临床试验

近日，制药公司 TG Therapeutics 表示， FDA 叫停了 Ukoniq （ umbralisib ）联合研究性抗 CD20 抗体 ublituximab 治疗CLL的临床试验。

BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究

CLL 患者的寿命会更长，而第二种恶性肿瘤对其生存的影响也变得越来越重要。研究团队发现发生黑色素瘤的 CLL 患者的 MSS、RFS 和潜在的免疫治疗不耐受性较差。

拓展阅读

【JCO】匹妥布替尼对比伊布替尼治疗初治和复发难治CLL/SLL的BRUIN CLL-314研究达到主要终点

为了研究匹妥布替尼是否能改善未经过BTKi治疗的CLL/SLL患者的预后，学者开展了一项 BRUIN CLL-314 研究。

Blood Cancer J：吡托布鲁替尼治疗慢性淋巴细胞白血病患者的药理特征及疾病进展分析

本研究系统分析了皮托布鲁替尼治疗慢性淋巴细胞白血病（CLL）患者的疗效与耐药机制，揭示了基线BTK突变、复发耐药状态及复杂核型等因素与疾病进展的关联，并探讨了联合用药策略以克服耐药。

【Med】含利沙托克拉（BCL2抑制剂）方案治疗慢性淋巴细胞白血病的1b/2 期研究结果

全球1b/2期研究显示，新型BCL-2抑制剂利沙托克拉单药或联合治疗CLL/SLL，耐受性良好，ORR最高97.7%，5-7天剂量递增降TLS风险，为高危及耐药患者供新选择。

【Blood Adv】国内多中心研究证实单克隆丙种球蛋白病可定义CLL的不同临床亚群

该研究旨在探索 MG 在不同治疗中对 CLL 患者的预后意义，为其在指导治疗策略中的实用性提供见解。

【Blood】共价BTK抑制剂和BCL2抑制剂治疗后，CLL如何治疗？

本文介绍了接受过cBTKis和BCL-2i治疗的CLL患者的管理方法，讨论了目前的治疗选择、巩固治疗的作用以及新兴策略的整合，以改善患者预后。

【Blood】伊布替尼一线治疗CLL/SLL的10年随访结果

9.6 年随访显示，伊布替尼一线治疗老年 CLL/SLL 中位 PFS 8.9 年，高危亚组获益显著，9 年 OS 率 68%，安全性可控。

NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2026.V1）

美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network) · 2025-10-10

2025 BSH指南：慢性淋巴细胞白血病的治疗

英国血液病学学会(BSH,British Society for Haematology) · 2025-10-09

2025 ASTCT临床实践建议：异基因造血细胞移植和嵌合抗原受体T-细胞治疗在慢性淋巴细胞白血病患者中的作用

美国移植与细胞治疗学会(ASTCT,American Society for Transplantation and Cellular Therapy) · 2025-06-11

2023 JSH实践指南：血液恶性肿瘤—淋巴瘤-5.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2025-03-01

慢性淋巴细胞白血病

暂未更新 · 2024-12-02

2024 新加坡共识指南：未经治疗的慢性淋巴细胞白血病的管理

国外血液科相关专家小组 · 2024-12-02